Eric Langer Joins Editorial Advisory Board of BioPharm International
Eric S. Langer, president and managing partner at BioPlan Associates, Inc. (Rockville, MD) has joined the Editorial Advisory Board of BioPharm International.
Eric S. Langer, president and managing partner at BioPlan Associates, Inc. (Rockville, MD) has joined the Editorial Advisory Board of BioPharm International.
Langer has more than 20 years’ experience in biotechnology and the life sciences, focused on international marketing management, market assessment, and publishing. He has published, edited, and authored numerous books, reports, and major studies about the industry, on topics such as: advances in biopharmaceutical technology in China, advances in large-scale biopharmaceutical manufacturing, biopharmaceuticals in the US market, cell culture, media, DNA/PCR purification, and many others. Langer teaches at Johns Hopkins University and American University and has developed numerous courses, classes, and seminar programs, including Marketing in a Regulated Environment, Marketing Technical Products, and TechniManagement. In 1989, Langer co-founded BioPlan Associates, Inc. a biotechnology and life sciences marketing company.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
